You can access any of the podium or poster presentations’ abstracts by searching for it below.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
HPS-142 - Pembrolizumab related Early-Onset Pancytopenia: A case report and literature review
- At: Copenhagen (Denmark) (2025)
- Type: Poster
- Poster code: HPS-142
- By: HSU, Wei Cheng (Department of Pharmacy, Cathay General Hospital, China Taiwan)
- Co-author(s): Ms Wei Cheng Hsu (Department of Pharmacy, Cathay General Hospital, Taipei, China Taiwan / Taipei Pharmacists Association, Taipei, China Taiwan)
Mrs Chi-Lan Kao (Department of Pharmacy, Cathay General Hospital, Taipei, China Taiwan / Taipei Pharmacists Association, Taipei, China Taiwan) - Abstract:
Background
Pembrolizumab, a PD-1 inhibitor, is approved for treating metastatic melanoma and other malignancies. While immune checkpoint inhibitors (ICIs) are known to cause immune-related adverse events (irAEs), hematologic toxicities such as pancytopenia remain rare. This report presents a suspected case of Pembrolizumab-induced pancytopenia,.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 2 July 2026